| ID | 70443 |
| FullText URL | |
| Author |
Furutani, Taiki
Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine
Okusha, Yuka
Department of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University
Kaken ID
researchmap
Nagami, Hiroki
Department of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University
Hanafusa, Hiroko
Department of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University
Tomida, Shuta
Center for Comprehensive Genomic Medicine, Okayama University Hospital
Kaken ID
researchmap
Sawada, Ryusuke
Department of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University
Hosono, Yasuyuki
Department of Pharmacology, Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama University
Kaken ID
researchmap
Nakatochi, Masahiro
Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine
|
| Abstract | p53, an important tumor suppressor protein, functions as a tetramer. Therefore, malignant variants in the tetramer-forming domain increase the likelihood of p53 dysfunction. Recent developments in genome analysis technology have expanded our understanding of malignant variants. However, variants of uncertain significance are also being increasingly identified. Hence, methods to assess the pathogenicity of these variants are required. In this study, we aimed to examine whether AlphaFold2 can be used to evaluate the functional impacts of p53 variants based on predicted three-dimensional (3D) structural information. For each variant present in datasets of p53 functional score, we performed 3D structural prediction using AlphaFold2. We analyzed the correlations among multiple AlphaFold2-derived scores to predict functional scores, such as protein stability and pathogenicity labels, for each dataset. The root-mean-square deviation obtained by comparing the 3D structures predicted by AlphaFold2 for the wild-type and variant structures showed a high correlation with each functional score. Overall, these findings indicate that AlphaFold2 can be used to evaluate variants.
|
| Keywords | 3D protein structural prediction
AlphaFold2
p53
tumor suppressor
variants of uncertain significance
|
| Published Date | 2026-04-07
|
| Publication Title |
Cancer Science
|
| Publisher | Wiley
|
| ISSN | 1347-9032
|
| NCID | AA11808050
|
| Content Type |
Journal Article
|
| language |
English
|
| OAI-PMH Set |
岡山大学
|
| Copyright Holders | © 2026 The Author(s).
|
| File Version | publisher
|
| PubMed ID | |
| DOI | |
| Web of Science KeyUT | |
| Related Url | isVersionOf https://doi.org/10.1111/cas.70380
|
| License | http://creativecommons.org/licenses/by-nc/4.0/|http://doi.wiley.com/10.1002/tdm_license_1.1
|
| Citation | T.Furutani, Y.Okusha, H.Nagami, et al., “ROWVA: A Structure-Based Metric for Predicting the Pathogenicity of Protein Variants Using Alphafold2,” Cancer Science (2026): 1–12, https://doi.org/10.1111/cas.70380.
|
| 助成情報 |
23kk0305020:
遺伝性腫瘍に見られるVUSに対する、包括的in vivoスクリーニングとin silico構造解析を融合した高精度機能的アノテーション
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
24wm0625301:
ALS多階層病態メカニズムの解明と治療法開発
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
21wm0425013:
孤発性ALS 患者メタボローム ・エクソソームmiRNA・蛋白質メチル 化を起点とする双方向 TR
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
25ama221612:
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
22H04923:
コホート・生体試料支援プラットフォーム
( 独立行政法人日本学術振興会 / Japan Society for the Promotion of Science )
22H03350:
プロテオームを中心としたトランスオミクス解析による生活習慣病発症機構の解明
( 独立行政法人日本学術振興会 / Japan Society for the Promotion of Science )
|